Kapoor Mayank, Swamy Anusha Mruthyunjaya, Sundriyal Deepak, Khanna Mridul, Sinha Nishant, J Karthik, Rajaram Shalini, Sehrawat Amit
Department of Medical Oncology, Hematology All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
Department of Obstretrics and Gynecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
Indian J Surg Oncol. 2025 Apr;16(2):401-407. doi: 10.1007/s13193-024-02103-9. Epub 2024 Sep 26.
Cancer incidence among women of childbearing potential (WCBP) underscores the need for effective fertility preservation strategies. Advances in cancer treatment have significantly improved survival rates, highlighting survivorship issues, particularly fertility concerns in younger patients. Chemotherapy, while a crucial treatment for cancer, often brings with it unintended consequences, particularly regarding fertility. Chemotherapy induces gonadotoxicity through mechanisms such as DNA damage, follicular apoptosis, and hormonal disruption, compromising ovarian function and fertility. The risk of infertility may be low, intermediate, or high depending upon the drug used, the dose, and the duration of use. Quantifying chemotherapy's impact is challenging due to diverse agents and variable effects. Guidelines recommend discussing fertility preservation options with WCBP before treatment, using biomarkers like anti-Mullerian hormone (AMH) to assess ovarian reserve. Strategies include cryopreservation of ovarian tissue, embryos, and oocytes, each with distinct advantages and considerations. Pharmacological interventions like GnRH agonists aim to mitigate gonadotoxic effects, although their efficacy is debated. Surgical approaches like oophoropexy protect ovaries during pelvic radiation but pose logistical challenges. Fertility preservation involves ethical and psychosocial dimensions, including informed consent, financial considerations, and ethical dilemmas, necessitating comprehensive patient counselling. Future research focuses on enhancing techniques such as in vitro maturation, developing artificial ovaries, and refining cryopreservation methods to optimize outcomes.
育龄期女性(WCBP)的癌症发病率凸显了有效生育力保存策略的必要性。癌症治疗的进展显著提高了生存率,凸显了生存问题,尤其是年轻患者的生育问题。化疗虽然是癌症的关键治疗方法,但往往会带来意想不到的后果,尤其是在生育方面。化疗通过DNA损伤、卵泡凋亡和激素紊乱等机制诱导性腺毒性,损害卵巢功能和生育能力。不孕风险可能低、中或高,这取决于所用药物、剂量和使用时间。由于化疗药物种类繁多且效果各异,量化化疗的影响具有挑战性。指南建议在治疗前与WCBP讨论生育力保存选项,使用抗苗勒管激素(AMH)等生物标志物评估卵巢储备。策略包括冷冻保存卵巢组织、胚胎和卵母细胞,每种方法都有各自的优点和注意事项。促性腺激素释放激素(GnRH)激动剂等药物干预旨在减轻性腺毒性作用,但其疗效存在争议。卵巢固定术等手术方法在盆腔放疗期间可保护卵巢,但存在后勤方面的挑战。生育力保存涉及伦理和社会心理层面,包括知情同意、经济考虑和伦理困境,因此需要对患者进行全面咨询。未来的研究重点是改进体外成熟等技术、开发人工卵巢以及完善冷冻保存方法以优化治疗效果。